Loading blog post…
A complete guide to inflammatory acne — how C. acnes drives the immune cascade that produces papules, pustules, nodules, and cysts, why nodular/cystic acne scars, and the evidence-based treatment ladder from BPO to isotretinoin.
· By MedSpot Editorial · 6 min read
Inflammatory acne — papules, pustules, nodules, and cysts — is acne where the immune system is actively responding to follicular disruption. Unlike comedonal acne (blackheads and whiteheads), inflammatory acne is painful, carries meaningful scarring risk, and requires anti-inflammatory and antibacterial treatment alongside comedolytic agents. Here's the complete pathophysiology and treatment framework.
A papule is a raised, red, solid bump less than 5 mm in diameter. It is the first visible inflammatory lesion — a follicle where the immune response is underway but the follicular wall has not yet ruptured. No pus visible.
A pustule is a papule that has filled with purulent material (pus) — dead neutrophils, bacteria, and sebum. The follicular wall has partially broken down. Visible white or yellow center. The classic "pimple."
A nodule is a large (>5 mm), deep, solid inflammatory lesion that extends into the dermis. It forms when the follicular wall ruptures, releasing sebum, keratin, and bacteria into the surrounding dermis — triggering an intense immune response. Nodules are painful, take weeks to resolve, and almost always scar if not treated early.
A cyst is a nodule that has formed a fluid-filled cavity surrounded by an epithelial lining. Technically "pseudocysts" in dermatology (true cysts are lined with epithelium) but the term is used clinically for large fluctuant lesions. The most severe form of inflammatory acne. Always scars without treatment.
All acne begins with a microcomedone — follicular plugging from excess sebum + keratinocyte hyperproliferation (see comedonal acne guide). Cutibacterium acnes (C. acnes) proliferates in the anaerobic, lipid-rich environment of the plugged follicle.
C. acnes expresses pattern-associated molecular patterns (PAMPs) — including surface lipoteichoic acid and peptidoglycan — that activate toll-like receptor 2 (TLR-2) on keratinocytes and sebocytes. TLR-2 activation → nuclear factor kappa B (NF-κB) pathway → pro-inflammatory cytokine release:
Neutrophils recruited by IL-8 → phagocytose C. acnes → release reactive oxygen species and proteases → follicular wall damage → rupture. Follicular contents (sebum, keratin, bacterial fragments) spill into dermis → foreign body granulomatous reaction → nodule or cyst.
The granulomatous dermal inflammation activates fibroblasts → collagen production in a disorganized pattern → acne scarring (icepick, rolling, boxcar, hypertrophic). The deeper the rupture, the more dermis involved, the greater the scarring risk.
Key implication: Every untreated nodule is a potential scar. Early aggressive treatment of nodular/cystic acne directly reduces the scarring burden.
The same C. acnes colonization produces wildly different inflammatory responses between individuals. This is explained by:
Benzoyl peroxide (BPO) 2.5–5%: The cornerstone of mild inflammatory acne treatment. BPO generates free radicals that penetrate the follicle → kill C. acnes → reduce inflammation. Crucially, C. acnes cannot develop resistance to BPO (oxidative mechanism, not enzymatic). Leyden et al. (1987, JAAD) established that 2.5% BPO is as effective as 10% with significantly less irritation — the concentration most commonly recommended today.
Adapalene 0.1% (OTC) + BPO 2.5% combination: Thiboutot et al. (2007, Journal of the American Academy of Dermatology): Adapalene 0.1% + BPO 2.5% gel vs. each component alone — combination significantly superior for both inflammatory and non-inflammatory lesions. The combination (available as Epiduo/Tactuo) is now considered a preferred first-line option for mild-moderate acne.
Application: BPO in AM; adapalene PM. Or Epiduo once daily PM to full face.
Topical antibiotics (clindamycin 1%, erythromycin 2%): Anti-inflammatory and antibacterial. Always combine with BPO — topical antibiotic monotherapy drives C. acnes resistance; BPO prevents this. Clindamycin 1% + BPO 5% fixed combinations (Benzaclin, Duac) are preferred over separate application.
Oral antibiotics (doxycycline 50–100 mg, minocycline 50–100 mg): For moderate-severe inflammatory acne not responding to topicals. Anti-inflammatory effect at sub-antimicrobial doses (same mechanism as for rosacea — inhibition of MMP expression and cytokine production). Doxycycline 50–100 mg/day or sub-antimicrobial dose doxycycline 40 mg/day (Oracea) are preferred.
Duration: 3–4 months maximum. Do not continue indefinitely — resistance develops in C. acnes and commensal bacteria. Maintain with BPO + topical retinoid as antibiotics are tapered.
Doxycycline vs. minocycline: Similar efficacy; doxycycline preferred for long-term use (lower risk of drug-induced lupus and pigmentation compared to minocycline).
Isotretinoin (oral): The most effective acne treatment available. Mechanism: isotretinoin → reduces sebaceous gland size by 35–90% (apoptosis of sebocytes) → dramatically reduces sebum → removes the substrate for C. acnes → normalizes follicular keratinization → anti-inflammatory effects.
Typically produces complete or near-complete remission in 85–90% of patients after one course. The only treatment that produces long-term remission after discontinuation (unlike all other acne treatments, which require maintenance).
Dosing: Weight-based 0.5–1 mg/kg/day; cumulative target 120–150 mg/kg for durable remission.
iPLEDGE REMS program: Required in the US for all prescribers and patients; monthly pregnancy tests for females of childbearing potential; isotretinoin is absolutely teratogenic (Category X).
Intralesional triamcinolone (ILT) for individual cysts: For acute, painful, individual nodules or cysts — intralesional injection of triamcinolone acetonide 2–5 mg/mL by a dermatologist flattens the lesion within 24–48 hours. The most rapid available treatment for a single severe inflammatory lesion. Prevents scarring of that specific lesion. Not a long-term management strategy — must be combined with systemic treatment.
Because inflammatory acne scars from the inside out (dermal inflammation → disorganized collagen), scarring prevention means treating inflammatory lesions early and aggressively — not waiting to "see if they resolve on their own."
Any nodular or cystic acne is an indication for prompt dermatology evaluation. Waiting until multiple nodules have occurred means waiting until multiple scars are forming.
Don't pick or squeeze: Mechanical trauma to inflammatory lesions ruptures the follicular wall more completely and drives inflammatory mediators deeper into the dermis — dramatically increasing scar depth and size.
After inflammatory acne is controlled:
Looking for an acne treatment consultation? Browse dermatology providers on MedSpot →